English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The powerful tools of genome editing are rapidly making their way toward the clinic. Zincfinger nucleases, TALENs, and CRISPR-Cas have all been used in conjunction with somatic cell therapies, and in vivo approaches are being tested. Both excitement and concern have been elicited by the prospects for gene editing in human embryos, a procedure that could eliminate the causes of particular genetic diseases in the treated individual and all of his/her descendants. A recent Nature article by Ma et al. provides a proof-of-principle demonstration of genome editing technologies to correct germline mutations, reporting targeted correction of the heterozygous MYBPC3 gene mutation that is responsible for hypertrophic cardiomyopathy in human preimplantation embryos (1). All of the genome editing platforms rely on the ability to design molecules that will make breaks in chromosomal DNA efficiently and specifically at a chosen target (2–5). In the case of CRISPR, the Cas9 protein acts as a nuclease when it is guided to its target by a specific single guide RNA (sgRNA). Breaks made by any of the platforms are recognized by cells as potentially lethal damage, and they are repaired by two alternative pathways: nonhomologous end joining (NHEJ), which often introduces new mutations at the break, and homology-dependent repair (HDR), which can use endogenous sequences or experimenter-provided DNA as a template. What was done? Ma [...] Viewpoint

Genome editing of human embryos: to edit or not to edit, that is the question